XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenues $ 770.4 $ 674.1 $ 2,249.9 $ 2,007.9
Operating expenses:        
Salaries and benefits 228.4 195.0 666.8 592.4
Supplies 201.4 179.2 589.9 549.8
Professional and medical fees 91.0 72.4 266.0 219.9
Lease expense 23.9 21.1 67.5 64.3
Other operating expenses 48.2 40.6 147.7 127.6
Cost of revenues 592.9 508.3 1,737.9 1,554.0
General and administrative expenses 29.2 36.8 102.7 100.0
Depreciation and amortization 50.2 28.9 118.7 87.0
Transaction and integration costs 29.4 12.8 66.1 37.3
Net loss on disposals, consolidations and deconsolidations 14.7 5.8 21.5 7.5
Equity in earnings of unconsolidated affiliates (5.2) (3.5) (12.3) (9.4)
Litigation settlements 0.5 3.6 (0.8) 8.1
Loss on debt extinguishment 0.0 0.0 5.1 0.0
Other income, net (2.2) (1.2) (10.7) (3.2)
Total operating expenses 709.5 591.5 2,028.2 1,781.3
Operating income 60.9 82.6 221.7 226.6
Interest expense, net (50.0) (49.8) (148.8) (144.3)
Income before income taxes 10.9 32.8 72.9 82.3
Income tax (expense) benefit (4.5) (3.1) (13.8) 6.3
Net income 6.4 29.7 59.1 88.6
Less: Net income attributable to non-controlling interests (38.1) (34.6) (118.7) (99.5)
Net loss attributable to Surgery Partners, Inc. $ (31.7) $ (4.9) $ (59.6) $ (10.9)
Net loss per share attributable to common stockholders:        
Basic (in USD per share) $ (0.25) $ (0.04) $ (0.47) $ (0.09)
Diluted (in USD per share) [1] $ (0.25) $ (0.04) $ (0.47) $ (0.09)
Weighted average common shares outstanding:        
Basic (shares) 126,172 125,747 126,093 125,559
Diluted (shares) [1] 126,172 125,747 126,093 125,559
[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.